ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Zacks Research

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

A number of other brokerages have also recently commented on ANIP. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $78.01 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals has a one year low of $56.71 and a one year high of $99.50. The stock has a market cap of $1.77 billion, a PE ratio of 19.75 and a beta of 0.46. The firm has a 50 day simple moving average of $77.29 and a two-hundred day simple moving average of $80.48.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter in the previous year, the company earned $1.70 EPS. The business’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts predict that ANI Pharmaceuticals will post 7.73 EPS for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 459 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total transaction of $36,357.39. Following the completion of the sale, the senior vice president directly owned 38,271 shares in the company, valued at $3,031,445.91. This represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Nikhil Lalwani sold 55,000 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the sale, the chief executive officer directly owned 349,889 shares of the company’s stock, valued at $27,140,889.73. The trade was a 13.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 100,564 shares of company stock valued at $7,800,862. 8.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ANIP. KBC Group NV purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at $28,000. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at $28,000. Hantz Financial Services Inc. boosted its position in ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 237 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in ANI Pharmaceuticals during the 4th quarter valued at $48,000. Finally, State of Wyoming purchased a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.